Movement Alert｜RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus06-16

On June 16, RemeGen (09995.HK) fell 5.06% in regular trading, trading at HKD 68.35/share, with turnover of HKD 129 million. The decline came amid broad-based weakness across Hong Kong-listed innovative drug stocks, as the sector has experienced accelerated selling pressure since early June.

Market concerns over renewed Federal Reserve rate hike expectations, uncertainties surrounding overseas BD (business development) deal prospects, and profit-taking following significant prior gains have combined to trigger persistent capital outflows from the innovative drug sector. Within the Biotechnology sector, Akeso fell 6.04%, 3SBio fell 4.74%, Innovent Biologics fell 1.62%, and BeiGene fell 0.19%, reflecting broadly depressed sector sentiment. Only SKB Bio posted a modest gain of 1.19%.

Notably, just one week earlier on June 9, RemeGen had rallied over 5% after its core product Telitacicept received approval for two new indications. The current pullback reflects broader macro and sector headwinds overriding company-specific positive catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195151901?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 13:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195151901","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure","media":"Market Focus","content":"<p><p>On June 16, RemeGen (09995.HK) fell 5.06% in regular trading, trading at HKD 68.35/share, with turnover of HKD 129 million. The decline came amid broad-based weakness across Hong Kong-listed innovative drug stocks, as the sector has experienced accelerated selling pressure since early June.</p><p>Market concerns over renewed Federal Reserve rate hike expectations, uncertainties surrounding overseas BD (business development) deal prospects, and profit-taking following significant prior gains have combined to trigger persistent capital outflows from the innovative drug sector. Within the Biotechnology sector, Akeso fell 6.04%, 3SBio fell 4.74%, Innovent Biologics fell 1.62%, and BeiGene fell 0.19%, reflecting broadly depressed sector sentiment. Only SKB Bio posted a modest gain of 1.19%.</p><p>Notably, just one week earlier on June 9, RemeGen had rallied over 5% after its core product Telitacicept received approval for two new indications. The current pullback reflects broader macro and sector headwinds overriding company-specific positive catalysts.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-16 13:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 16, RemeGen (09995.HK) fell 5.06% in regular trading, trading at HKD 68.35/share, with turnover of HKD 129 million. The decline came amid broad-based weakness across Hong Kong-listed innovative drug stocks, as the sector has experienced accelerated selling pressure since early June.</p><p>Market concerns over renewed Federal Reserve rate hike expectations, uncertainties surrounding overseas BD (business development) deal prospects, and profit-taking following significant prior gains have combined to trigger persistent capital outflows from the innovative drug sector. Within the Biotechnology sector, Akeso fell 6.04%, 3SBio fell 4.74%, Innovent Biologics fell 1.62%, and BeiGene fell 0.19%, reflecting broadly depressed sector sentiment. Only SKB Bio posted a modest gain of 1.19%.</p><p>Notably, just one week earlier on June 9, RemeGen had rallied over 5% after its core product Telitacicept received approval for two new indications. The current pullback reflects broader macro and sector headwinds overriding company-specific positive catalysts.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1195151901","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195151901","pubTimestamp":1781587047,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 16, RemeGen (09995.HK) fell 5.06% in regular trading, trading at HKD 68.35/share, with turnover of HKD 129 million. The decline came amid broad-based weakness across Hong Kong-listed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"异动快讯|RemeGen常规交易跌5.06%香港创新药板块持续抛压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 16, RemeGen (09995.HK) fell 5.06% in regular trading, trading at HKD 68.35/share, with turnover of HKD 129 million. The decline came amid broad-based weakness across Hong Kong-listed innovative drug stocks, as the sector has experienced accelerated selling pressure since early June.Market concerns over renewed Federal Reserve rate hike expectations, uncertainties surrounding overseas BD (business development) deal prospects, and profit-taking following significant prior gains have combined to trigger persistent capital outflows from the innovative drug sector. Within the Biotechnology sector, Akeso fell 6.04%, 3SBio fell 4.74%, Innovent Biologics fell 1.62%, and BeiGene fell 0.19%, reflecting broadly depressed sector sentiment. Only SKB Bio posted a modest gain of 1.19%.Notably, just one week earlier on June 9, RemeGen had rallied over 5% after its core product Telitacicept received approval for two new indications. The current pullback reflects broader macro and sector headwinds overriding company-specific positive catalysts.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195151901","isCrawlerRequest":true}